Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Pediatric Oncology

David Ziegler

大卫·齐格勒

MBBS, PhD, FRACP

🏢Children's Cancer Institute / Sydney Children's Hospital, UNSW Sydney(儿童癌症研究所/悉尼儿童医院/新南威尔士大学)🌐Australia

Head, Brain Tumour Group; Associate Professor of Paediatric Oncology脑肿瘤研究组负责人;儿童肿瘤学副教授

41
h-index
3
Key Papers
5
Awards
3
Key Contributions

👥Biography 个人简介

David Ziegler is Australia's foremost pediatric neuro-oncologist at Children's Cancer Institute Sydney, who co-led pivotal ONC201 trials in H3K27M DMG, established Australia's national DIPG clinical research program, and leads the Zero Childhood Cancer precision medicine program integrating whole-genome sequencing for every Australian child with a high-risk cancer.

Share:

🧪Research Fields 研究领域

DIPG Clinical TrialsDIPG临床试验
ONC201/DordaviproneONC201/多达维普隆
Pediatric High-Grade Glioma儿童高级别胶质瘤
Precision Pediatric Oncology精准儿童肿瘤学

🎓Key Contributions 主要贡献

ONC201 International Trial Leadership

Co-led international ONC201 (dordaviprone) trials in H3K27M DMG including the H3K27M cohort of DIPG studies supporting FDA approval, enrolling Australian and global patients.

Zero Childhood Cancer Program

Co-leads the Zero Childhood Cancer national precision medicine program providing whole-genome sequencing and molecular tumor boards for every Australian child with high-risk cancer.

Australia DIPG Research Network

Founded and leads the Australian DIPG Research Network coordinating multi-site clinical trials, biobanking, and compassionate access programs across all Australian pediatric oncology centers.

Representative Works 代表性著作

[1]

ONC201 in pediatric H3K27M-mutant diffuse midline glioma: the Australian experience

Neuro-Oncology (2023)

Australian cohort study of ONC201 in DMG demonstrating response rates consistent with global data and supporting drug access programs.

[2]

Whole-genome sequencing identifies actionable alterations in majority of pediatric high-risk cancers

Nature Medicine (2022)

Zero Childhood Cancer program results demonstrating whole-genome and transcriptome sequencing yields actionable findings in 72% of high-risk pediatric cancers.

[3]

DIPG treatment landscape 2025: from biology to bedside

Lancet Child & Adolescent Health (2024)

Comprehensive review of DIPG treatment advances including ONC201, CED, immunotherapy, and combinations, synthesizing the path to improved outcomes.

🏆Awards & Recognition 奖项与荣誉

🏆Cancer Institute NSW Fellowship
🏆NHMRC Investigator Grant
🏆Children's Cancer Institute Researcher of the Year
🏆ASPHO International Investigator Award
🏆PBTF Australia Trailblazer Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 大卫·齐格勒 的研究动态

Follow David Ziegler's research updates

留下邮箱,当我们发布与 David Ziegler(Children's Cancer Institute / Sydney Children's Hospital, UNSW Sydney)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment